Interdisziplinäre Therapie von Hirnmetastasen
Tóm tắt
Từ khóa
Tài liệu tham khảo
https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.4/LL_Mammakarzinom_Langversion_4.4.pdf. Zugegriffen: 26. Dez. 2023
https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.3.pdf. Zugegriffen: 26. Dez. 2023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726093/pdf/cureus-0015-00000048941.pdf. Zugegriffen: 26. Dez. 2023
Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71. https://doi.org/10.1016/S1470-2045(12)70432-1
Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124(1):142–155. https://doi.org/10.1038/s41416-020-01175-y
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28:1840–1847
Bartsch R, Jerzak KJ, Larrouquere L, Müller V, Le Rhun E (2023) Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treat Rev. https://doi.org/10.1016/j.ctrv.2023.102653
Bernhardt et al https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581806/. Zugegriffen: 26. Dez. 2023
Brower JV, Saha S, Rosenberg SA, Hullett CR, Robins IH (2016) Management of leptomeningeal metastases: prognostic factors and associated outcomes. J Clin Neurosci 27:130–137. https://doi.org/10.1016/j.jocn.2015.11.012
Brown PD et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. A randomized clinical trial. JAMA 316(4):401–409. https://doi.org/10.1001/jama.2016.9839
Brown PD et al (2020) Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38(10):1019–1029. https://doi.org/10.1200/JCO.19.02767
Chen TW‑W (2023) Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.5456
Chew Minmin S et al (2023) Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases. Breast Cancer Res Treat 199(1):99–107. https://doi.org/10.1007/s10549-023-06908-0
Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449–1454. https://doi.org/10.1212/WNL.0b013e3181dc1a69
Cortés J, Rugo HS, Awada A et al (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 165(2):329–341
Cortes J, Kim SB, Chung WP, DESTINY-Breast03 Trial Investigators et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143–1154
Diehl CD et al (2022) Low-energy X‑ray intraoperative radiation therapy (lex-IORT) for resected brain metastases: a single-institution experience. Cancers 15(1):14. https://doi.org/10.3390/cancers15010014
Diéras V, Weaver R, Tolaney SM et al (2021) Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Res 81(4):PD13–7
El Shafie RA et al (2018) Palliative radiotherapy for leptomeningeal carcinomatosis—analysis of outcome, prognostic factors, and symptom response. Front Oncol 8:641. https://doi.org/10.3389/fonc.2018.00641
Franzoi MA, Hortobagy GN (2019) Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol 135:85–94. https://doi.org/10.1016/j.critrevonc.2019.01.020
Freedman RA, Gelman RS, Anders CK et al (2019) TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2‑positive breast cancer and brain metastases. J Clin Oncol 37(13):1081–1089
Gondi V et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265–282. https://doi.org/10.1016/j.prro.2022.02.003
Heßler N et al (2022) Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting. BMC Cancer 22(1):275. https://doi.org/10.1186/s12885-022-09317-6
Hulsbergen AFC et al (2020) Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol 22(8):1173–1181. https://doi.org/10.1093/neuonc/noaa013
Hurvitz S, Kim S‑B, Chung W‑P et al (2021) Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
Hurvitz S, Kim S‑B, Chung W‑P, Im S‑A, Park Y, Hegg R et al (2021) Abstract GS3-01: trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-breast03 SABCS https://doi.org/10.1158/1538-7445.SABCS21-GS3-01
Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S et al (2021) Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist 26(8):e1327–e38. https://doi.org/10.1002/onco.13830
Kalkanis SN et al (2010) The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):33–43. https://doi.org/10.1007/s11060-009-0061-8
Kim JS, Kim IA (2020) Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol 12:1758835920936117. https://doi.org/10.1177/1758835920936117
Krieg SM et al (2013) Reliability of intraoperative neurophysiological monitoring using motor evoked potentials during resection of metastases in motor-eloquent brain regions: clinical article. J Neurosurg 118(6):1269–1278. https://doi.org/10.3171/2013.2.JNS121752
Krieg SM et al (2016) Resection of motor eloquent metastases aided by preoperative nTMS-based motor maps-comparison of two observational cohorts. Front Oncol 6:261. https://doi.org/10.3389/fonc.2016.00261
Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M et al (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26(1):113–119. https://doi.org/10.1093/annonc/mdu486
Kuksis M, Yizhuo G, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23(6):894–904. https://doi.org/10.1093/neuonc/noaa285
Le Rhun E (2023) Eptomeningeal metastasis from solid tumors: EANO–ESMO clinical practice guideline for diagnosis, treatment and follow-up https://doi.org/10.1016/j.esmoop.2023.101624
Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A et al (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83–92. https://doi.org/10.1007/s11060-013-1092-8
Le Rhun E et al (2021) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32(11):1332–1347. https://doi.org/10.1016/j.annonc.2021.07.016
Lee SJ, Lee J‑I, Nam D‑H, Ahn YC, Han JH, Sun J‑M et al (2013) Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 8:185–191. https://doi.org/10.1097/JTO.0b013e3182773f21
Lin NU, Murthy RK, Abramson V et al (2021) Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A et al (2021) Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a phase II study. J Clin Oncol 39(24):2667–2675. https://doi.org/10.1200/JCO.20.02822
Lin NU, Murthy RK, Abramson V et al (2023) Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 9:197–205
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E (2023) Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. Jama Oncol 9:197–205
Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753–763
Merenzon MA et al (2023) Towards the definition of progressive disease in brain metastasis treated with laser ablation: an evidence-based study. J Neurooncol 163(2):463–471. https://doi.org/10.1007/s11060-023-04360-0
Mollica L (2021) Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis. DIC. https://doi.org/10.7573/dic.2021-6-6
Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E et al (2020) Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31(10):P1350–P58. https://doi.org/10.1016/j.annonc.2020.06.020
Muller V, Bartsch R, Lin NU, Montemurro F, Pegram MD, Tolaney SM (2023) Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review. Cancer Treat Rev 115:102527
Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21(5):942-8. https://doi.org/10.1093/annonc/mdp407
Pérez-García JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J et al (2022) Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. https://doi.org/10.1093/neuonc/noac144
Perez-Garcia JM, Vaz Batista M, Cortez P et al (2023) Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol 25:157–166
Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R et al (2015) CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33(14):1564–1573. https://doi.org/10.1200/JCO.2014.57.1794
Puri S et al (2023) Systemic treatment for brain metastasis and Leptomeningeal disease in breast cancer patients. Curr Oncol Rep 25(12):1419–1430. https://doi.org/10.1007/s11912-023-01468-4
Saura C, Oliveira M, Feng YH et al (2020) Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38(27):3138–3149
Schebesch K‑M et al (2023) Brain metastasis resection: the impact of fluorescence guidance (MetResect study). Neurosurg Focus 55(2):E10. https://doi.org/10.3171/2023.5.FOCUS23197
Sollmann N et al (2018) Associations between clinical outcome and navigated transcranial magnetic stimulation characteristics in patients with motor-eloquent brain lesions: a combined navigated transcranial magnetic stimulation-diffusion tensor imaging fiber tracking approach. J Neurosurg 128(3):800–810. https://doi.org/10.3171/2016.11.JNS162322
Sperduto PW et al (2020) Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol 22(9):1359–1367. https://doi.org/10.1093/neuonc/noaa025
Tolaney SM, Sahebjam S, Le Rhun E et al (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26(20):5310–5319
Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A et al (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26(20):5310–5319. https://doi.org/10.1158/1078-0432.CCR-20-1764
Wang R, Zhu Y, Liu X et al (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19(1):1091. https://doi.org/10.1186/s12885-019-6311-z
Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772
Witzel I, Laakmann E, Weide R, Neunhoffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Wurschmidt F, Schem C, Bechtner C, Wurstlein R, Fehm T, Mobus V, Burchardi N, Loibl S, Muller V (2018) Treatment and outcomes of patients in the brain metastases in breast cancer network registry. Eur J Cancer 102:1–9